SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bratt Ola) "

Sökning: WFRF:(Bratt Ola)

  • Resultat 41-50 av 141
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  • Bratt, Ola, et al. (författare)
  • Palliativ cancervård är en betydande del av urologin. Studie av det sista levnadsåret för patienter som dog av urologisk cancer
  • 2002
  • Ingår i: Läkartidningen. - 0023-7205. ; 99:8, s. 765-770
  • Tidskriftsartikel (refereegranskat)abstract
    • A total of 330 in-patient episodes at the urology ward, with a mean duration of 9.8 days, were registered in a study of 100 patients who died from urological cancer. Twelve patients spent more than two months of their last year of life at the urology ward. As many as 82% of the admittances were on an emergency basis. A total of 101 operations were performed on 84 patients; 47 patients received palliative radiotherapy. This patient category needs a great deal of palliative care--at short notice--in order to get an optimal quality of life. Although many symptoms could have been alleviated outside hospital, the majority of patients needed specialised urological hospital care during their last year of life.
  •  
42.
  • Bratt, Ola, 1963, et al. (författare)
  • Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men
  • 2023
  • Ingår i: European Urology. - 0302-2838 .- 1873-7560.
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The European Union recently recommended evaluation of the feasibility of organised prostate cancer screening. In Sweden, regional population-based organised prostate cancer testing (OPT) programmes were introduced in 2020. Objective: To describe initial participation rates and diagnostic outcomes. Design, setting, and participants: The three most populated Swedish regions invited all men aged 50 yr to OPT by a letter in 2020–2022. Men with prostate-specific antigen (PSA) ≥3 ng/ml were referred for prostate magnetic resonance imaging (MRI). PSA assays differed across regions. Men with Prostate Imaging Reporting and Data System (PI-RADS) 1–3 and PSA density ≥0.15 ng/ml/cm3 or PI-RADS 4–5 were referred for a biopsy. Data were obtained from the Swedish Register for Organised Prostate Cancer Testing. Outcome measurements and statistical analysis: Overall and regional participation rates, PSA distributions, PI-RADS score distributions, cancer detection, and treatment were evaluated. Results and limitations: A total of 23 855 (35%) of 68 060 invited men participated; 696 (2.9%) had PSA ≥3 ng/ml, and of them, 306 (44%) had a biopsy indication and 221 (32%) had a biopsy. On biopsy, 93 (42%) had Gleason grade group ≥2 (0.39% of PSA-tested men) and 44 (20%) Gleason grade group 1 cancer. Most men with cancer had treatment with curative intent (70%) or were under active surveillance (28%). Across regions, proportions of men with PSA ≥3 ng/ml ranged from 2.3% to 4.0%, and those with PI-RADS score 4–5 ranged from 12% to 21%. A limitation is that results are applicable only to first testing of men in their early 50s. Conclusions: The OPT programmes are feasible with good compliance to the diagnostic pathway. The use of MRI and PSA density avoided a biopsy for over half of the men with PSA ≥3 ng/ml. Inter-regional differences in diagnostic outcomes show a need for standardisation of the diagnostic pathway's components. Patient summary: We report the diagnostic outcomes of inviting 68 000 50-yr-old men to organised prostate cancer testing.
  •  
43.
  • Bratt, Ola, et al. (författare)
  • Prostatacancercentrum - navet i framtidens prostatacancersjukvård
  • 2017
  • Ingår i: Läkartidningen. - 0023-7205. ; 114:5
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • Prostate cancer is the most common form of cancer in Sweden. The past decade has seen a tremendous development of new methods for diagnosing, staging, treating and rehabilitating men with suspicious or confirmed prostate cancer. This development necessitates a multidisciplinary and multiprofessional approach to the management of men with suspicious or confirmed prostate cancer. A recent survey showed that currently few Swedish men with prostate cancer receive the quality of care that is outlined in the national clinical guidelines. Specialised prostate cancer units are increasingly common in Europe, but as yet there are no such units in Sweden. We believe that the creation of prostate cancer units in Sweden would be an essential step forward, towards an improved future care of men with prostate cancer.
  •  
44.
  • Bratt, Ola, et al. (författare)
  • Prostatacancercentrum – navet i framtidens prostatacancersjukvård - En vision som är i linje med det nationella vårdprogrammets riktlinjer : En vision som är i linje med det nationella vårdprogrammets riktlinjer
  • 2017
  • Ingår i: Läkartidningen. - 0023-7205. ; 114
  • Forskningsöversikt (övrigt vetenskapligt/konstnärligt)abstract
    • Prostate cancer units - hubs in the future care of men with prostate cancer Prostate cancer is the most common form of cancer in Sweden. The past decade has seen a tremendous development of new methods for diagnosing, staging, treating and rehabilitating men with suspicious or confirmed prostate cancer. This development necessitates a multidisciplinary and multiprofessional approach to the management of men with suspicious or confirmed prostate cancer. A recent survey showed that currently few Swedish men with prostate cancer receive the quality of care that is outlined in the national clinical guidelines. Specialised prostate cancer units are increasingly common in Europe, but as yet there are no such units in Sweden. We believe that the creation of prostate cancer units in Sweden would be an essential step forward, towards an improved future care of men with prostate cancer.
  •  
45.
  • Bratt, Ola, et al. (författare)
  • Prostataspecifikt antigen--den viktigaste cancermarkören. Diagnostik och uppföljning av prostatacancer har förändrats markant.
  • 2007
  • Ingår i: Läkartidningen. - 0023-7205. ; 104:46, s. 3460-3464
  • Tidskriftsartikel (refereegranskat)abstract
    • Vid de nivåer av PSA (prostataspecifikt antigen) där en botbar prostatacancer eventuellt skulle kunna diagnostiseras är godartad prostataförstoring vanligare än cancer. Urinvägsinfektioner ger ofta en påtaglig och långvarig ökning av PSA. Vid undersökningsfynd eller symtom som inger misstanke om prostatacancer ska PSA alltid analyseras. Screening med PSA för tidig diagnostik av prostatacancer utvärderas i stora, randomiserade studier. I väntan på resultat från dessa kan varken allmän screening eller PSAtestning vid hälsokontroll rekommenderas. Enligt Socialstyrelsen ska män som önskar hälsokontroll med PSA erbjudas skriftlig och muntlig information samt individuell värdering av möjlig nytta och risk. En broschyr för detta ändamål kommer att distribueras under hösten 2007.
  •  
46.
  • Bratt, Ola, et al. (författare)
  • Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease : a population-based study from the National Prostate Cancer Register of Sweden
  • 2010
  • Ingår i: Scandinavian Journal of Urology and Nephrology. - : Informa Healthcare. - 0036-5599 .- 1651-2065. ; 44:6, s. 384-390
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. To investigate the effects of prostate-specific antigen (PSA) testing of men without clinical signs of prostate cancer on the incidence of prostate cancer in Sweden. Material and methods. Information on the cause of diagnosis, tumour characteristics and primary treatment for patients diagnosed with prostate cancer between January 1999 and December 2007 was extracted from the National Prostate Cancer Register of Sweden. This register includes data for 95% of Swedish prostate cancer cases. Results. The total age-standardized annual incidence of prostate cancer per 100 000 men increased from 187 in 1999 to 233 in 2004, but decreased thereafter to 196 in 2007. The incidence of asymptomatic cases also peaked in 2004 (at 62 per 100 000 men), but varied six-fold between different counties in that year (16–98 per 100 000 men). Asymptomatic cases (n = 17 143) constituted 15% of all new cases in 2000 and 30% in 2007. Almost as many cases were diagnosed in stage T1c in men with symptoms, usually from the lower urinary tract. Together these two groups constituted 29% of all new cases in 2000 and 52% in 2007. It was estimated that at least one-third of all Swedish men aged 50–75 years had a PSA test between 2000 and 2007. Conclusions. Even though screening for prostate cancer is not recommended in Sweden, PSA testing of men without clinical signs of prostate cancer is common. The effects on the Swedish incidence of prostate cancer were similar to those reported from the USA.
  •  
47.
  • Bratt, Ola, 1963, et al. (författare)
  • Prostate cancer in kidney transplant recipients - a nationwide register study
  • 2020
  • Ingår i: Bju International. - : Wiley. - 1464-4096 .- 1464-410X. ; 125:5, s. 679-685
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective To investigate whether post-transplantation immunosuppression negatively affects prostate cancer outcomes in male kidney transplant recipients. Patients and Methods We used the Swedish Renal Register and the National Prostate Cancer Register to identify all kidney transplantation recipients diagnosed with prostate cancer in Sweden 1998-2016. After linking these registers with Prostate Cancer Database Sweden (PCBaSe), a case-control study was designed to compare time period and risk category-specific probabilities of a prostate cancer diagnosis amongst kidney transplantation recipients versus the male general population. The registers did not include information about the specific immunosuppression agent used in all transplantation recipients. Data from PCBaSe were used to compare prostate cancer characteristics at diagnosis and survival for patients with prostate cancer with versus without a kidney transplant. Propensity score matching, Cox regression analysis and Fisher's exact test were used and 95% confidence intervals (CIs) calculated. Results Almost half of the 133 kidney transplantation recipients were transplanted before the mid-1990s, when PSA testing became common. The transplant recipients were not more likely than age-matched control men to be diagnosed with any (odds ratio [OR] 0.84, 95% CI 0.70-0.99) or high-risk or metastatic prostate cancer (OR 0.84, 95% CI 0.62-1.13). None of the ORs for the different categories of prostate cancer increased with time since transplantation. Cancer characteristics at the time of diagnosis and cancer-specific survival were similar amongst transplant recipients and the control group of 665 men diagnosed with prostate cancer without a kidney transplant. Conclusions This Swedish nationwide, register-based study gave no indication that immunosuppression after kidney transplantation increases the risk of prostate cancer or adversely affects prostate cancer outcomes. The study suggests that men with untreated low-grade prostate cancer can be accepted for transplantation.
  •  
48.
  •  
49.
  •  
50.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 41-50 av 141
Typ av publikation
tidskriftsartikel (127)
forskningsöversikt (9)
konferensbidrag (3)
doktorsavhandling (2)
Typ av innehåll
refereegranskat (121)
övrigt vetenskapligt/konstnärligt (20)
Författare/redaktör
Bratt, Ola (81)
Bratt, Ola, 1963 (55)
Stattin, Pär (47)
Garmo, Hans (20)
Bill-Axelson, Anna (19)
Adolfsson, Jan (19)
visa fler...
Ahlgren, Göran (14)
Holmberg, Lars (13)
Lambe, Mats (11)
Damber, Jan-Erik, 19 ... (9)
Hugosson, Jonas, 195 ... (9)
Akre, Olof (9)
Johansson, Eva (8)
Liedberg, Fredrik (7)
Loeb, Stacy (7)
Johansson, Jan-Erik (7)
Garmo, H. (7)
Carlsson, S (6)
Stattin, P (6)
Adolfsson, J. (5)
Egevad, Lars (5)
Carlsson, Stefan (5)
Van Hemelrijck, Miek ... (5)
Lilja, Hans (4)
Lyttkens, Kerstin (4)
Kjölhede, Henrik, 19 ... (4)
Lambe, M (4)
Varenhorst, Eberhard (4)
Törnblom, Magnus (4)
Widmark, Anders (4)
Andrén, Ove (4)
Akre, O (4)
Godtman, Rebecka Arn ... (4)
Robinson, D. (3)
Almquist, Helen (3)
Montorsi, Francesco (3)
Berglund, Anders (3)
Andren, Ove, 1963- (3)
Damber, Jan-Erik (3)
Hellström, Magnus (3)
Holmberg, Erik (3)
Hugosson, Jonas (3)
Nilsson, Per (3)
Bjartell, Anders (3)
Jäderling, Fredrik (3)
Stranne, Johan, 1970 (3)
Fransson, Per (3)
Carlsson, Sigrid, 19 ... (3)
Jiborn, Thomas (3)
Wallström, Jonas (3)
visa färre...
Lärosäte
Lunds universitet (68)
Göteborgs universitet (64)
Uppsala universitet (37)
Umeå universitet (25)
Karolinska Institutet (14)
Örebro universitet (8)
visa fler...
Chalmers tekniska högskola (4)
Linköpings universitet (2)
Malmö universitet (1)
visa färre...
Språk
Engelska (132)
Svenska (9)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (138)
Naturvetenskap (2)
Teknik (2)
Lantbruksvetenskap (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy